

**TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.**

**INTERIM REPORT AS OF THE 30<sup>th</sup> OF SEPTEMBER 2017**

**INTERIM STATEMENT OF FINANCIAL STATUS  
AS OF THE 30.09.2017**

	<b>30.09.2017</b>	<b>31.12.2016</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	26 072	25 888
Intangible assets	3 450	3 644
Investments with minority interest	1	1
Trade receivables	6 080	6 025
<b>Total non-current assets</b>	<b>35 603</b>	<b>35 558</b>
<b>Current assets</b>		
Inventories	5 561	5 082
Trade and other receivables	52 653	50 373
Financial assets with maturity		24
Purchased own shares	8	
Cash and cash equivalents	45	50
<b>Total current assets</b>	<b>58 267</b>	<b>55 529</b>
<b>Total assets</b>	<b>93 870</b>	<b>91 087</b>
<b>LIABILITIES</b>		
<b>Equity capital</b>		
Registered capital	64 300	56 600
Statutory reserves	8 695	7 810
Undistributed profit	5 617	8 585
<b>Total</b>	<b>78 612</b>	<b>72 995</b>
<b>Non-current liabilities</b>		
Long-term loans	698	1 015
Deferred tax liabilities	1 284	1 284
Liabilities to employees on retirement	67	67
<b>Total non-current liabilities</b>	<b>2 049</b>	<b>2 366</b>
<b>Current liabilities</b>		
Trade and other liabilities	2 752	2 909
Short-term loans	9 777	11 349
Current part of long-term loans	571	869
Current corporate tax		55
Other tax payables	109	544
<b>Total current liabilities</b>	<b>13 209</b>	<b>15 726</b>
<b>Total liabilities</b>	<b>15 258</b>	<b>18 092</b>
<b>Total equity capital and liabilities</b>	<b>93 870</b>	<b>91 087</b>

Draft date: 25.10.2017


Sofia

Prepared by:.....

/ D. Jecheva /

Director:.....

/B. Georgiev/



**TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.****INTERIM REPORT AS OF THE 30<sup>th</sup> OF SEPTEMBER 2017****INTERIM STATEMENT OF COMPREHENSIVE INCOME  
AS OF THE 30.09.2017**

	<b>30.09.2017</b>	<b>30.09.2016</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenues	25 926	24 587
Other income	34	3
<b>Total income</b>	<b>25 960</b>	<b>24 590</b>
Balance value of assets sold	(1 465)	(3 120)
Changes in inventories of products and work in progress	246	302
Cost for materials and services	(12 798)	(8 623)
Employee costs	(2 479)	(2 282)
Amortization costs	(2 294)	(2 655)
Other expenses	(795)	(452)
Financial income	84	176
Financial expenses	(268)	(401)
<b>Total expenses</b>	<b>(19 769)</b>	<b>(17 055)</b>
<b>Profit before taxation</b>	<b>6 191</b>	<b>7 535</b>
Corporate tax cost	(574)	(754)
<b>Profit/Loss for the period</b>	<b>5 617</b>	<b>6 781</b>
<b>Other comprehensive income for the period</b>		
<b>Total comprehensive income for the period</b>		
Income per share / in BGN per 1 share /	0.10	0.12

Draft date : 25.10.2017

Sofia

Prepared by:.....  
/ D. Jecheva /Director:.....  
/B. Georgiev/

**INTERIM CASH FLOW REPORT  
AS OF THE 30.09.2017**

	<b>30.09.2017</b>	<b>30.09.2016</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flow from operating activities</b>		
Revenues from produce, goods and services	22 955	18 059
Payments to suppliers of materials, goods and services	(11 233)	(9 651)
Payments to personnel	(2 428)	(1 535)
Payments of interest and dividends		(31)
Corporate tax payments	(629)	(796)
Other revenues/payments	(4 218)	(5 099)
<b>Net cash flow</b>	<b>4 447</b>	<b>947</b>
<b>Cash flow form investment activities</b>		
Payments for non-current assets acquired	(2 027)	(854)
<b>Net cash flow</b>	<b>(2 027)</b>	<b>(854)</b>
<b>Cash flow from financial activities</b>		
Revenues from loans received	133	2 347
Payments for the reacquisition of securities	(8)	
Payments for loans received	(1 700)	(597)
Payment of interest, dividends	(186)	(214)
Payment for finance lease	(665)	(1 602)
Other revenues/payments		
<b>Net cash flow</b>	<b>(2 426)</b>	<b>(66)</b>
<b>Change of cash and cash equivalents</b>		
	<b>(6)</b>	<b>27</b>
Cash and cash equivalents at the beginning of the period	51	40
Cash and cash equivalents at the end of the period	45	67

Draft date: 25.10.2017

Sofia

Prepared by:.....

/ D. Jecheva /



Director:.....

/B. Georgiev /

**TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.**

**INTERIM REPORT AS OF THE 30<sup>th</sup> OF SEPTEMBER 2017**

**INTERIM STATEMENT OF CHANGES IN EQUITY  
AS OF THE 30.09.2017**

	Appendices	Registered capital BGN'000	Revaluation reserves BGN'000	Other reserves BGN'000	Undistributed profit/loss BGN'000	Total equity BGN'000
<b>Balance as of 01.01.2016</b>	<b>7,8</b>	<b>49 600</b>	<b>2 711</b>	<b>3 881</b>	<b>7 780</b>	<b>63 972</b>
Profit/loss for the period					8 585	8 585
Other comprehensive income	8		438			438
Including from tax effect of the revaluation of property, plant and equipment			(50)			(50)
<b>Total comprehensive income</b>			<b>438</b>		<b>8 585</b>	<b>9 023</b>
Issue of shares by the owners		7 000			(7 000)	
Accrued dividends						
Accrued tantiemmes						
Transferred to profit reserves	8			780	(780)	
<b>Total recognized amount of income and expenses for the period</b>		<b>7 000</b>		<b>780</b>	<b>(7 780)</b>	
<b>Balance as of 31.12.2016</b>	<b>7,8</b>	<b>56 600</b>	<b>3 149</b>	<b>4 661</b>	<b>8 585</b>	<b>72 995</b>
<b>Balance as of 01.01.2017</b>	<b>7,8</b>	<b>56 600</b>	<b>3 149</b>	<b>4 661</b>	<b>8 585</b>	<b>72 995</b>
Profit/loss for the period					5 617	5 617
Other comprehensive income	8					
<b>Total comprehensive income</b>					<b>5 617</b>	<b>5 617</b>
Issue of shares by the owners		7 700		885	(8 585)	
Accrued dividends						
Accrued tantiemmes						
Transferred to profit reserves	8					
<b>Total recognized amount of income and expenses for the period</b>						
<b>Balance as of 30.09.2017</b>	<b>7,8</b>	<b>64 300</b>	<b>3 149</b>	<b>5 546</b>	<b>5 617</b>	<b>78 612</b>

Draft date: 25.10.2017

Sofia

Prepared by:.....

/D.Jecheva/

Director:.....

/B. Georgiev /

